Rare Diseases Clinical Research Network Contact Registry

Last updated

The Rare Diseases Clinical Research Network (RDCRN) Contact Registry [1] [2] is a patient contact registry started in 2004 and sponsored by the National Institutes of Health (NIH). [3] [4] The RDCRN Contact Registry collects and stores the contact information of people who want to participate in RDCRN-sponsored research or learn more about RDCRN research. It connects patients with researchers in order to advance rare disease research. [5] [6]

Contents

The Rare Diseases Clinical Research Network (RDCRN) [7] is a U.S.-based research network funded by the NIH. It fosters research to better understand, diagnose, and treat rare diseases. Its 20 consortia—teams of scientists, physicians, and patients—each study a group of related rare diseases. Established by Congress under the Rare Diseases Act of 2002, the RDCRN is an initiative of the Office of Rare Diseases Research at the NIH's National Center for Advancing Translational Sciences. Future research may produce helpful information for those with rare diseases.

Individuals who are 18 years of age and older and have a rare disease, are a caregiver for someone with a rare disease, or an unaffected individual can join the RDCRN registry. The contact registry collects basic data (i.e. contact information, diagnosis, medical history) to be stored in a secure, computerized database hosted by the RDCRN's Data Management and Coordinating Center based at Cincinnati Children's Hospital Medical Center.

Function

The registry collects and maintains the contact information of people who want to:

It allows patients and others to connect with research teams and patient advocacy groups focused on particular diseases. data about individuals who are interested in receiving information about rare disease research and opportunities for research participation. The registry supports the dissemination of information relevant to the RDCRN community. It also offers RDCRN investigators and patient advocacy groups access to data that will help them assess the feasibility of conducting a proposed study.

Funding

The RDCRN Contact Registry is operated by the Rare Diseases Clinical Research Network which is funded by the National Institutes of Health and led by the National Center for Advancing Translational Sciences through its Office of Rare Diseases Research. It is governed by the RDCRN Contact Registry Oversight Committee. The contact registry is hosted and maintained by the RDCRN's Data Management and Coordinating Center at Cincinnati Children's Hospital Medical Center.

Related Research Articles

A rare disease is a disease that affects a small percentage of the population. In some parts of the world, the term orphan disease describes a rare disease whose rarity results in little or no funding or research for treatments, without financial incentives from governments or other agencies. Orphan drugs are medications targeting orphan diseases.

<span class="mw-page-title-main">Health informatics</span> Computational approaches to health care

Health informatics is the study and implementation of computer structures and algorithms to improve communication, understanding, and management of medical information. It can be view as branch of engineering and applied science.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is one of the institutes and centers that make up the National Institutes of Health, an agency of the United States Department of Health and Human Services (HHS).

The National Center for Research Resources (NCRR) was a center within the National Institutes of Health, a United States government agency. NCRR provided funding to laboratory scientists and researchers for facilities and tools in the goal of curing and treating diseases.

Orphanet is an organisation and knowledge base dedicated to rare diseases as well as corresponding diagnosis, orphan drugs, clinical trials and expert networks.

Translational research is research aimed at translating (converting) results in basic research into results that directly benefit humans. The term is used in science and technology, especially in biology and medical science. As such, translational research forms a subset of applied research.

TREAT-NMD is a global academic network that focuses on advancing research in neuromuscular disorders. It was established in 2007 with its coordination centre at the Newcastle University. As of 2018, the network comprises over a hundred research centres and patient organisations from 54 countries as well as independent academics and patient representatives. The network's aim is to provide infrastructure to accelerating research through supporting collaboration between its members. Its main goals include improving trial-readiness worldwide, advancing patient diagnosis and care and accelerating pre-clinical research.

<span class="mw-page-title-main">Food Allergy Research & Education</span>

Food Allergy Research & Education (FARE) is a non-profit, private organization dedicated to food allergy awareness, research, education, and advocacy. FARE's goal is to enhance the lives of people with food allergies by providing support and resources to help them live safe yet productive lives. FARE also includes information for people without food allergies, who are looking to not only be respectful of others but also become more educated and gain more awareness regarding healthcare and treatments. The organization provides information, programs, and resources about food allergies and anaphylaxis, a severe, potentially life-threatening allergic reaction. Working on behalf of more than 32 million Americans who have potentially life-threatening food allergies, FARE's mission is to improve the quality of life and health of those with food allergies and to provide hope for the development of new treatments and diagnostics.

Patient participation is a trend that arose in answer to medical paternalism. Informed consent is a process where patients make decisions informed by the advice of medical professionals.

The International Fibrodysplasia Ossificans Progressiva Association (IFOPA) is a US-based 501(c)(3) non-profit organization supporting medical research, education and communication for those afflicted by the rare genetic condition Fibrodysplasia Ossificans Progressiva (FOP). IFOPA's mission is to fund research to find a cure for FOP while supporting, connecting, and advocating for individuals with FOP and their families, and raising awareness worldwide. IFOPA is governed by a volunteer board of directors which may range in number from 9 to 15, at least one of whom must have FOP. The association's location is 1520 Clay St., Suite H2, North Kansas City, MO, 64116, part of the Kansas City, Missouri metropolitan area.

The National Center for Advancing Translational Sciences (NCATS) was established on December 23, 2011 and is located in Bethesda, Maryland. NCATS is one of 27 institutes and centers of the U.S. National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services. The mission of NCATS is to transform scientific discoveries into new treatments and cures for disease that can be delivered faster to patients. The budget provided to NCATS for fiscal year 2018 is $557,373,000.

<span class="mw-page-title-main">National Institutes of Health Clinical Center</span>

The NIH Clinical Center is a hospital solely dedicated to clinical research at the National Institutes of Health campus in Bethesda, Maryland. The Clinical Center, known as Building 10, consists of the original part of the hospital, the Warren Grant Magnuson Clinical Center, and the newest addition, the Mark O. Hatfield Clinical Research Center. The two parts are connected to form one large building.

The Rare Diseases Clinical Research Network (RDCRN) is an initiative of the US Office of Rare Diseases Research (ORDR). RDCRN is funded by the ORDR, the National Center for Advancing Translational Sciences and collaborating institute centers. The RDCRN is designed to advance medical research on rare diseases by providing support for clinical studies and facilitating collaboration, study enrollment and data sharing. Through the RDCRN consortia, physician scientists and their multidisciplinary teams work together with patient advocacy groups to study more than 200 rare diseases at sites across the nation.

The Pancreatic Cancer Action Network (PanCAN) is a United States-based 501(c)(3) charity that funds research, provides patient/caregiver support, conducts community outreach and advocates for increased federal research funding for those affected by pancreatic cancer.

<span class="mw-page-title-main">Rare Diseases Act of 2002</span> US law

The Rare Disease Act of 2002 is a law passed in the United States that establishes the statutory authorization for the Office of Rare Diseases as a federal entity able to recommend a national research agenda, coordinate research, and provide educational activities for researchers.

The Undiagnosed Diseases Network (UDN) is a research study that is funded by the National Institutes of Health Common Fund. Its purpose is to bring together clinical and research experts from across the United States to solve the most challenging medical mysteries using advanced technologies.

<span class="mw-page-title-main">Office of Rare Diseases Research</span>

The Office of Rare Diseases Research is a division of the US National Center for Advancing Translational Sciences (NCATS) that oversees the Rare Diseases Clinical Research Network and Genetic and Rare Diseases Information Center.

Real world data (RWD) in medicine is data derived from a number of sources that are associated with outcomes in a heterogeneous patient population in real-world settings, including but not limited to electronic health records, health insurance claims and patient surveys. While no universal definition of real world data exists, researchers typically understand RWD as distinct from data sourced from randomized clinical trials.

<span class="mw-page-title-main">Melissa Haendel</span> American bioinformaticist

Melissa Anne Haendel is an American bioinformaticist who is the Chief Research Informatics Officer of the Anschutz Medical Campus of the University of Colorado as well as a Professor of Biochemistry and Molecular Genetics and the Marsico Chair in Data Science. She serves as Director of the Center for Data to Health (CD2H). Her research makes use of data to improve the discovery and diagnosis of diseases. During the COVID-19 pandemic, Haendel joined with the National Institutes of Health to launch the National COVID Cohort Collaborative (N3C), which looks to identify the risk factors that can predict severity of disease outcome and help to identify treatments.

<span class="mw-page-title-main">Jung-Min Lee</span> South Korean-American medical oncologist and physician-scientist

Jung-Min Lee is a South Korean-American medical oncologist and physician-scientist focused on the early clinical drug development and translational studies of targeted agents in BRCA mutation-associated breast or ovarian cancer, high-grade epithelial ovarian cancer, and triple-negative breast cancer. She is a NIH Lasker Clinical Research Scholar and principal investigator in the Women's Malignancies Branch at the National Cancer Institute.

References

  1. ↑ "RDCRN Launches Contact Registry to Connect Patients, Researchers and Advance Rare Disease Research". Rare Diseases Clinical Research Network. Retrieved 2022-03-15.
  2. ↑ "RDCRN Contact Registry". Rare Diseases Clinical Research Network. Retrieved 2022-03-15.
  3. ↑ Groft, Stephen C.; Gopal-Srivastava, Rashmi (2013). "A model for collaborative clinical research in rare diseases: experience from the Rare Disease Clinical Research Network program" (PDF). Clinical Investigation. 3 (11).
  4. ↑ Richesson, Rachel L.; Sutphen, Rebecca; Shereff, Denise; Krischer, Jeffrey P. (July 2012). "The Rare Diseases Clinical Research Network Contact Registry update: Features and functionality". Contemporary Clinical Trials . 33 (4): 647–656. doi:10.1016/j.cct.2012.02.012. PMC   3652679 . PMID   22405970.
  5. ↑ Merkel, Peter A.; Manion, Michele; Gopal-Srivastava, Rashmi; Groft, Stephen; Jinnah, H. A.; Robertson, David; Krischer, Jeffrey P. (December 2016). "The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network". Orphanet Journal of Rare Diseases . 11 (1): 66. doi: 10.1186/s13023-016-0445-8 . ISSN   1750-1172. PMC   4870759 . PMID   27194034.
  6. ↑ Richesson, R. L.; Lee, H. S.; Cuthbertson, D.; Lloyd, J.; Young, K.; Krischer, J. P. (January 2009). "An automated communication system in a contact registry for persons with rare diseases: Scalable tools for identifying and recruiting clinical research participants". Contemporary Clinical Trials . 30 (1): 55–62. doi:10.1016/j.cct.2008.09.002. PMC   2640948 . PMID   18804556.
  7. ↑ "Home | Rare Diseases Clinical Research Network". rdcrn.org. Retrieved 2022-03-15.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.